AlphAIalphai — Financial news for AI agents
yahoo.comAUG 202 min read$EL

Estée Lauder Q4 2026 earnings beat, fiscal 2027 profit forecast

Estée Lauder reported fiscal 2026 earnings of $2.51 per share, exceeding expectations, with revenue of $3.63 billion. The company forecasted fiscal 2027 EPS between $3.10 and $3.35, above analyst estimates. Fragrance sales grew 10%, while skin care increased 4%. Mainland China sales rose 9%. The stock gained 8% premarket.

Original reporting
yahoo.com
Published Aug 20, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Estée Lauder Q4 2026 earnings beat, fiscal 2027 profit forecast — source image
Source · yahoo.com
Decision brief

The 30-second read

$ELBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest stronger demand in fragrance and skin‑care, supporting a bullish short‑term outlook.

02

Market read

Earnings beat drives immediate price action and may influence sector sentiment.

03

What to watch

Potential headwinds from tariff costs and slower growth in makeup could temper longer‑term upside.

Relevance 8/10Novelty 8/10Timing: premarket today

Background

Estée Lauder posted Q4 revenue of $3.63B vs. $3.54B estimate and FY2026 EPS of $2.51, with FY2027 EPS guidance of $3.10‑$3.35.

Company-level read

Ticker impact

$ELBullishHigh confidence
Context

Estée Lauder reported Q4 2026 earnings beat and raised FY 2027 profit forecast, sending the stock up ~8% premarket.

Expected impact

Expect continued premarket rally, potential intraday gain of 3-5% before broader market digestion.

Evidence & confidence

Beat on revenue and EPS, plus guidance above estimates, drives immediate buying pressure.

Market effects

Sector

Strong results may boost broader beauty and consumer discretionary sector sentiment.

Regional

Positive impact on North American consumer stocks; modest uplift for Asian markets with Estée Lauder exposure.

Global

Earnings beat from a major global brand reinforces confidence in post‑pandemic consumer recovery.

Counterpoint

What could challenge this read

If the market has already priced in the beat, the stock could face short‑term profit taking.

Key entities

  • Company
    Estée Lauder Companies Inc.

    Global beauty products manufacturer.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 20
$ELHighAI 9/10

Why Estee Lauder Rallied This Week

Estee Lauder (EL) shares rose 11.8% this week after its Q4 earnings beat estimates, with revenue up 6.5% to $3.63B and EPS up 333% to $0.39. The company also provided optimistic guidance, expecting 3-5% revenue growth and 24-34% EPS growth for the next fiscal year. Management highlighted $1.2B in cost cuts and increased customer investments.

fool.com2 min
AUG 20
$ELMed

Sources: Shein Aims to IPO on September 1

French regulators fined Boohoo 2.33 million euros for deceptive trade practices, including misleading sale prices and material descriptions. Estee Lauder forecasted annual profit above estimates, citing strong demand for premium fragrances and skincare. Shein aims for a $25 billion valuation in its Hong Kong IPO, down from $100 billion four years ago.

aawsat.com3 min
AUG 20
$MRNAHighAI 9/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) shares surged 176.97% to $174.38 after a successful cancer therapy trial with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01, reporting $3.63B revenue and raising its margin forecast. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

baystreet.ca2 min
AUG 20
$MRNAMed

Dow Jones Today: The Treasury Just Did Something the Bond Market Desperately Needed

The Treasury announced it would double buybacks of longer-term notes, causing 30-year Treasury yields to drop to 5.194% and the Dow Jones to close up 0.22%. Fed minutes indicated potential rate hikes if inflation persists. Moderna's stock surged 175% after successful cancer vaccine trial data. Bitcoin rose above $68,000, driven by Treasury optimism and crypto legislation interest.

financial-news.co.uk4 min
AUG 20
$MRNAMed

US stocks snap losing streak on Treasury move, solid profits

U.S. stocks rose after the Treasury announced plans to double purchases of longer-term Treasurys, easing bond market pressure. The S&P 500 gained 0.2%, ending a 3-day losing streak. Strong earnings from Estee Lauder, Target, and others also supported gains. Moderna and Merck surged on positive cancer vaccine trial results. The 10-year Treasury yield fell to 4.64% from 4.71%.

asahi.com3 min
AUG 19
$MRNAMedAI 8/10

Wall Street recovers as yields ease; Moderna lifts healthcare stocks

U.S. indexes rebounded as bond yields eased, with Moderna's shares more than doubling after positive trial results. Merck rose 11.2%, and healthcare stocks gained. Tech stocks were flat, with Broadcom down 4% and Marvell up 9.8%. The Dow, S&P 500, and Nasdaq all rose. Target and Estee Lauder also reported positive updates.

spokesman.com3 min